UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 24.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 100,020 shares of the specialty pharmaceutical company's stock after buying an additional 19,824 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.18% of Supernus Pharmaceuticals worth $3,617,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Raiffeisen Bank International AG purchased a new stake in shares of Supernus Pharmaceuticals in the 4th quarter valued at about $25,000. Smartleaf Asset Management LLC increased its position in shares of Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock worth $47,000 after purchasing an additional 870 shares during the last quarter. Mark Sheptoff Financial Planning LLC purchased a new stake in Supernus Pharmaceuticals in the fourth quarter valued at approximately $52,000. Headlands Technologies LLC lifted its position in Supernus Pharmaceuticals by 203.0% during the fourth quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company's stock valued at $55,000 after purchasing an additional 1,015 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. bought a new stake in Supernus Pharmaceuticals during the fourth quarter valued at approximately $72,000.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Cantor Fitzgerald reissued a "neutral" rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th. Wall Street Zen raised Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, May 16th.

Supernus Pharmaceuticals Stock Performance

NASDAQ:SUPN traded up $0.81 during mid-day trading on Friday, reaching $33.15. The stock had a trading volume of 354,750 shares, compared to its average volume of 480,715. The stock has a market capitalization of $1.86 billion, a P/E ratio of 30.98 and a beta of 0.74. The firm has a 50 day moving average price of $31.92 and a two-hundred day moving average price of $34.49. Supernus Pharmaceuticals, Inc. has a one year low of $25.53 and a one year high of $40.28.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.